

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM603714

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Release of First Lien Security Interest
SEQUENCE:	1

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
JPMorgan Chase Bank, N.A.		10/19/2020	Association: UNITED STATES

RECEIVING PARTY DATA

Name:	Vector Laboratories, Inc.
Street Address:	30 Ingold Road
City:	Burlingame
State/Country:	CALIFORNIA
Postal Code:	94010
Entity Type:	Corporation: CALIFORNIA
Name:	TriLink BioTechnologies, LLC
Street Address:	10770 Wateridge Circle, Suite 200
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92121
Entity Type:	Limited Liability Company: DELAWARE
Name:	Glen Research, LLC
Street Address:	22825 Davis Drive, Suite 100
City:	Sterling
State/Country:	VIRGINIA
Postal Code:	20164
Entity Type:	Limited Liability Company: DELAWARE

PROPERTY NUMBERS Total: 19

Property Type	Number	Word Mark
Registration Number:	2006391	ELITE
Registration Number:	1426136	PHOTOPROBE
Registration Number:	1635200	V!
Registration Number:	1755996	VECTASHIELD
Registration Number:	1220471	VECTASTAIN
Registration Number:	1259009	VECTOR

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	1542135	VECTREX
Registration Number:	3268400	CHROMALINK
Registration Number:	4542383	MAGNALINK
Registration Number:	4488606	NANOLINK
Registration Number:	5024276	THE MODIFIED NUCLEIC ACID EXPERTS
Registration Number:	5304533	OLIGOBUILDER
Registration Number:	5468487	CLEANCAP
Registration Number:	5468481	CLEANTAG
Registration Number:	5032541	TRILINK
Registration Number:	5082758	TRILINK BIOTECHNOLOGIES
Registration Number:	5082759	TRILINK BIOTECHNOLOGIES
Registration Number:	5528329	CLEANAMP
Serial Number:	87939792	

CORRESPONDENCE DATA

Fax Number: 8009144240

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 800-713-0755

Email: Michael.Violet@wolterskluwer.com, ECarrera@cahill.com

Correspondent Name: CT Corporation

Address Line 1: 4400 Easton Commons Way

Address Line 2: Suite 125

Address Line 4: Columbus, OHIO 43219

NAME OF SUBMITTER:	Elaine Carrera
SIGNATURE:	/Elaine Carrera/
DATE SIGNED:	10/19/2020

Total Attachments: 10
source=a15. Maravai - 1L IP Release (Trademarks)#page1.tif
source=a15. Maravai - 1L IP Release (Trademarks)#page2.tif
source=a15. Maravai - 1L IP Release (Trademarks)#page3.tif
source=a15. Maravai - 1L IP Release (Trademarks)#page4.tif
source=a15. Maravai - 1L IP Release (Trademarks)#page5.tif
source=a15. Maravai - 1L IP Release (Trademarks)#page6.tif
source=a15. Maravai - 1L IP Release (Trademarks)#page7.tif
source=a15. Maravai - 1L IP Release (Trademarks)#page8.tif
source=a15. Maravai - 1L IP Release (Trademarks)#page9.tif
source=a15. Maravai - 1L IP Release (Trademarks)#page10.tif

RECORDATION FORM COVER SHEET TRADEMARKS ONLY

To the Director of the U. S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies):

JPMorgan Chase Bank, N.A.

- Individual(s)
- Partnership
- Corporation- State: _____
- Other _____
- Association
- Limited Partnership

Citizenship (see guidelines) USA

Additional names of conveying parties attached? Yes No

3. Nature of conveyance/Execution Date(s) :

Execution Date(s) October 19, 2020

- Assignment
- Security Agreement
- Other Release of First Lien Security Interest
- Merger
- Change of Name

2. Name and address of receiving party(ies)

Additional names, addresses, or citizenship attached? Yes No

Name: Vector Laboratories, Inc.

Street Address: 30 Ingold Road

City: Burlingame

State: CA

Country: USA Zip: 94010

- Individual(s) Citizenship _____
- Association Citizenship _____
- Partnership Citizenship _____
- Limited Partnership Citizenship _____
- Corporation Citizenship USA-CA
- Other _____ Citizenship _____

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No
(Designations must be a separate document from assignment)

4. Application number(s) or registration number(s) and identification or description of the Trademark.

A. Trademark Application No.(s) Text
See Schedule B

B. Trademark Registration No.(s)
See Schedule B

Additional sheet(s) attached? Yes No

C. Identification or Description of Trademark(s) (and Filing Date if Application or Registration Number is unknown):

5. Name & address of party to whom correspondence concerning document should be mailed:

Name: Elaine Carrera, Senior Paralegal

Internal Address: _____

Street Address: c/o Cahill Gordon & Reindel LLP,
32 Old Slip

City: New York

State: NY Zip: 10005

Phone Number: (212) 701-3365

Docket Number: _____

Email Address: ecarrera@cahill.com

6. Total number of applications and registrations involved:

19

7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$ _____

- Authorized to be charged to deposit account
- Enclosed

8. Payment Information:

Deposit Account Number _____

Authorized User Name _____

9. Signature:

Elaine Carrera
Signature

October 19, 2020
Date

Elaine Carrera

Name of Person Signing

Total number of pages including cover sheet, attachments, and document:

10

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0148, or mailed to: Mail Stop Assignment Recordation Branch, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

Addendum to Cover Page of Trademarks Form Cover Sheet

2. Name and address of receiving party(ies)

TriLink BioTechnologies, LLC, a Delaware Limited Liability Company
10770 Wateridge Circle, Suite 200
San Diego, CA 92121
Citizenship – USA – DE

Glen Research, LLC, a Delaware Limited Liability Company
22825 Davis Drive, Suite 100
Sterling, VA 20164
Citizenship – USA – DE

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

This RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this “Release”), dated as of October 19, 2020 (the “Effective Date”), is made by JPMorgan Chase Bank, N.A., in its capacity as Collateral Agent (the “Agent”), in favor of the grantor parties identified on the signature page hereto (each a “Grantor” and collectively, the “Grantors”).

WHEREAS, pursuant to that certain First Lien Security Agreement, dated as of August 2, 2018, by and among the Agent, the Grantors and certain other parties thereto (as amended, amended and restated, or otherwise modified from time to time, the “Security Agreement”), the Grantors granted to the Agent, in its capacity as Collateral Agent, a security interest in and continuing lien on certain collateral;

WHEREAS, pursuant to the Security Agreement, the Grantors executed and delivered a First Lien Intellectual Property Security Agreement, dated as of August 2, 2018 (the “Intellectual Property Security Agreement”), for recordal with the United States Patent and Trademark Office;

WHEREAS, the Intellectual Property Security Agreement was recorded with the United States Patent and Trademark Office on August 2, 2018 at Reel/Frame 046708/0095 and Reel/Frame 6421/0737;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Security Agreement or the Intellectual Property Security Agreement, as applicable.

2. Release. The Agent, without representation or warranty of any kind, hereby releases, discharges, terminates and cancels all of its security interest in and lien on the Patent Collateral, including the patents and patent applications set forth on Schedule A attached hereto, the Trademark Collateral, including the trademark registrations and applications set forth on Schedule B attached hereto, in each case arising under the Security Agreement and the Intellectual Property Security Agreement, and all other Collateral (as defined in the Intellectual Property Security Agreement) arising under the Intellectual Property Security Agreement, and hereby authorizes and requests that the United States Patent and Trademark Office note and record the release hereby given and any other filings necessary to evidence the release and termination of the Agent’s rights under the Security Agreement and/or Intellectual Property Security Agreement with respect to the Patent Collateral and the Trademark Collateral, and under the Intellectual Property Security Agreement with respect to all other Collateral (as defined in the Intellectual Property Security Agreement). If and to the extent that the Agent has acquired any right, title or interest in and to the Patent Collateral or the Trademark Collateral under the Security Agreement and/or Intellectual Property Security Agreement, or any other Collateral (as defined in the Intellectual Property Security Agreement) under the Intellectual Property Security Agreement, the Agent, without representation or warranty of any kind, hereby re-transfers, re-conveys and re-assigns such right, title or interest to the Grantors.

3. Termination. The Agent, without representation or warranty of any kind, terminates and cancels the Intellectual Property Security Agreement.

4. Further Assurances. The Agent agrees to take all further actions, and provide to the Grantors and their successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably

requested by the Grantors, at the Grantors' sole cost and expense, to more fully and effectively effectuate the purposes of this Release.

5. Counterparts. This Release may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

6. Governing Law. This Release shall be governed exclusively under the laws of the State of New York, without regard to conflicts of law or choice of law principles.

[Signature pages follow]

IN WITNESS WHEREOF, the Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date:

**JPMORGAN CHASE BANK, N.A., acting in
its capacity as Collateral Agent for the
Secured Parties**

By:  _____

Name: Dawn Lee Lum

Title: Executive Director

GRANTORS:

VECTOR LABORATORIES, INC.
TRILINK BIOTECHNOLOGIES, LLC
GLEN RESEARCH, LLC

By: 
Name: Kevin Herde
Title: Chief Financial Officer

[Signature Page to First Lien IP Release]

SCHEDULE A

PATENTS

Assignee	Title	Country	Issued Date
TriLink BioTechnologies, Inc.	Pre-activated Carbonyl Linkers for the Modification of Oligonucleotides	United States	6320041 11/20/2001
TriLink BioTechnologies	Phosphotriester-Modified Oligonucleotide Primers for Nucleic Acid Amplification	United States	8361753 01/29/2013
TriLink BioTechnologies	Chemically Modified Nucleoside 5'-Triphosphates for Thermally Initiated Amplification of Nucleic Acid	United States	8133669 03/13/2012
TriLink BioTechnologies	Chemically Modified Ligase Cofactors, Donors and Acceptors	United States	8728725 05/20/2014
TriLink BioTechnologies, LLC	Functional biopolymer modification reagents and uses thereof	United States	7102024 09/05/2006
TriLink BioTechnologies, LLC	Functional biopolymer modification reagents and uses thereof	United States	7732628 06/08/2010
TriLink BioTechnologies, LLC	Functional biopolymer modification reagents and uses thereof	United States	RE46171 10/04/2016
TriLink BioTechnologies, LLC	Hydrazine-based and carbonyl-based bifunctional crosslinking reagents	United States	6800728 10/05/2004
TriLink BioTechnologies, LLC	Hydrazine-based and carbonyl-based bifunctional crosslinking reagents	United States	7462689 12/09/2008
TriLink BioTechnologies, LLC	Hydrazone-based and oxime-based fluorescent and chromophoric/pro-flourescent and pro-chromophoric reagents and linkers	United States	8541555 09/24/2013
TriLink BioTechnologies, LLC	Preparation and/or purification of oligonucleotide conjugates	United States	8846875 09/30/2014
TriLink BioTechnologies, LLC	Biomolecule/polymer conjugates	United States	6911535 06/28/2005
TriLink BioTechnologies, LLC	Triphosphate oligonucleotide modification reagents and uses thereof	United States	7999098 08/16/2011

Assignee	Title	Country	Issued Date
TriLink BioTechnologies, LLC	Triphosphate oligonucleotide modification reagents and	United States	7173125 02/06/2007
TriLink BioTechnologies, LLC	Triphosphate oligonucleotide modification reagents and	United States	6686461 02/03/2004
Glen Research, LLC (f/k/a Glen Research Corporation)	Universal supports for oligonucleotide synthesis	United States	6770754 8/3/2004
Glen Research, LLC (f/k/a Glen Research Corporation)	Universal supports for oligonucleotide synthesis	United States	7491817 2/17/2009
Glen Research, LLC (f/k/a Glen Research Corporation); Nelson Biotechnologies, Inc.	Novel reagents utilizing a serinol scaffold for synthetic oligonucleotide	United States	8394948 3/12/2013
Glen Research, LLC (f/k/a Glen Research Corporation); Berry & Associates	Fluorescent nitrogenous base and nucleosides incorporating same	United States	7144995 12/5/2006
TriLink BioTechnologies, Inc.	Chemically Modified Ligase Cofactors, Donors and Acceptors	United States	9631227 04/25/2017

PATENT APPLICATIONS

Assignee	Title	Country	Application Serial No.	Filing Date
TriLink BioTechnologies, Inc.	Chemically modified ligase cofactors, donors and acceptors	United States	15495848	04/24/2017

SCHEDULE B

TRADEMARKS

Owner	Mark	Country	Registration No. / Date
Vector Laboratories, Inc.	Elite	United States	2006391 10/8/1996
Vector Laboratories, Inc.	Photoprobe	United States	1426136 1/27/1987
Vector Laboratories, Inc.	V! and Design	United States	1635200 2/19/1991
Vector Laboratories, Inc.	Vectashield	United States	1755996 3/2/1993
Vector Laboratories, Inc.	Vectastain	United States	1220471 12/21/1982
Vector Laboratories, Inc.	Vector	United States	1259009 11/29/1983
Vector Laboratories, Inc.	Vectrex	United States	1542135 6/6/1989
TriLink BioTechnologies, LLC	CHROMALINK	United States	3268400 07/24/2007
TriLink BioTechnologies, LLC	MAGNALINK	United States	4542383 06/3/2014
TriLink BioTechnologies, LLC	NANOLINK	United States	4488606 02/25/2014
TriLink BioTechnologies, LLC	THE MODIFIED NUCLEIC ACID EXPERTS	United States	5024276 08/16/2016
TriLink BioTechnologies, LLC	OLIGOBUILDER	United States	5304533 10/10/2017

Owner	Mark	Country	Registration No. / Date
TriLink BioTechnologies, LLC	CLEANCAP	United States	5468487 05/15/2018
TriLink BioTechnologies, LLC	CLEANTAG	United States	5468481 05/15/2018
TriLink BioTechnologies, LLC	TRILINK	United States	5032541 08/30/2016
TriLink BioTechnologies, LLC	TRILINK BIOTECHNOLOGIES	United States	5082758 11/15/2016
TriLink BioTechnologies, LLC	TRILINK BIOTECHNOLOGIES & Design	United States	5082759 11/15/2016
TriLink BioTechnologies, LLC	CLEANAMP	United States	5528329 7/31/2018

TRADEMARK APPLICATIONS

Owner	Mark	Country	Application Serial No.	Filing Date
TriLink BioTechnologies, LLC	Design	United States	87939792	05/29/2018